Production & Sales

Roche agrees to sell eczema drug rights to Dermira

Dermira has signed a licensing agreement with Roche to secure exclusive rights to lebrikizumab, a monoclonal antibody targeting interleukin 13 (IL-13), for atopic dermatitis and all other indications.

Emergent BioSolutions to buy GSK’s anthrax treatment raxibacumab

Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m.

ABPI applies for Judicial Review against new procedures for cost-effective medicines

The Association of the British Pharmaceutical Industry (ABPI) has applied for judicial review over new procedures that restrict access to cost-effective medicines.

Pfizer breaks ground on new R&D facility in Missouri

Pfizer has broke ground on a research and development (R&D) and process development facility at 875 W. Chesterfield Parkway, Chesterfield in the US state of Missouri.

Eli Lilly completes $90m expansion of biotechnology center in San Diego

Eli Lilly and Company has completed the $90m expansion of its biotechnology center in San Diego, California, US.

Bristol-Myers Squibb to divest Irish manufacturing facility to SK Biotek

Bristol-Myers Squibb has agreed to divest its small molecule active pharmaceutical ingredient manufacturing facility in Swords, Ireland, to South Korea based SK Biotek, a subsidiary of SK Holdings.

Perrigo CEO to retire, search committee created to find replacement

Perrigo said its current CEO John Hendrickson is retiring and it has started a search for a replacement.

Bristol-Myers’ opdivo approved in Europe for urothelial carcinoma

Bristol-Myers Squibb’s Opdivo (nivolumab) has been approved by the European Commission (EC) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-based therapy.

Roquette to acquire Brazilian pharmaceutical tablet maker Itacel

Plant-based ingredient manufacturer Roquette has agreed to buy Brazilian pharmaceutical tablet maker Itacel.